Eliquis earns best safety score in its class in analysis of FDA adverse event reports

Tracy Staton What's the safest anticoagulant? According to AdverseEvents, which analyzes and distills data filed with the FDA, that would be Eliquis, the latest entrant into the ...

Report: Abingworth tees up $330M-plus to bankroll biotech bets

Damian Garde Life sciences venture outfit Abingworth is creeping up on a close for its 6th fund, according to Dow Jones Venturewire, reportedly outstripping its goal of $ 330 million ...

FDA OKs AstraZeneca’s rare disease drug, but only for a subset of patients

Damian Garde The FDA approved AstraZeneca's drug for a diabetes-related rare disease, but, following a vote from a panel of advisers, only for a portion of a tiny patient population, ...

Ranbaxy scrambles to fix problems that challenge its exclusives

Eric Palmer In an effort to get itself into a place where it can again ship from its FDA-approved plants in India, Ranbaxy Laboratories says it is taking a hard look at how it runs ...

Corporate VCs back $49M round for dermatology player

John Carroll Novo Ventures has stepped up to lead a $ 49 million round for San Diego-based Thesan Pharmaceuticals, which is developing new dermatology drugs for conditions like acne ...

Endo to pay $193M to wrap up Justice Department’s off-label marketing probe

Carly Helfand Sales whistleblowers have struck again, this time landing Endo Health Solutions in a $ 193 million hole. FiercePharma News

Activist Denner gets his way with a board seat at troubled Ariad

Carly Helfand Alex Denner has taken a seat with the board of directors at Ariad–a position he demanded back in October when the company's only approved drug, Iclusig, ran ...

CURx picks up a Gilead cystic fibrosis drug ready for Phase III

Damian Garde San Diego startup CURx has paid an undisclosed sum to license an antiobitic developed by Gilead, planning to launch a Phase III trial on the drug to treat lung infections ...

Eisai’s revved-up Belviq marketing starting to pay off, analysts say

Carly Helfand When it comes to addressing the market, pharma has three P's, according to Eisai's Michael O'Brien: physician, payer and patient. And as VP of specialty marketing, ...

Incyte’s new CEO says his pipeline is underrated–and undervalued

Damian Garde Incyte doesn't get the respect it deserves, according to CEO Hervé Hoppenot, and, after about a month on the job, the biotech's new chief is hyping his company's ...

Biotech IPOs: Class of 2014 still rolling as investors line up to cash in

Damian Garde The most likely indicator of whether biotech's Wall Street hot streak can last is whether investors are getting good returns on all these drug developer IPOs. And so ...

Twitter praises Boehringer for social media savvy

Carly Helfand Which pharma companies are getting it right when it comes to social media? As far as Twitter is concerned, Boehringer Ingelheim is up there. FiercePharma News
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS